• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Transplant immunology >Dual antibody induction and de novo use of everolimus enable low-dose tacrolimus with early corticosteroid withdrawal in simultaneous pancreas-kidney transplantation
【24h】

Dual antibody induction and de novo use of everolimus enable low-dose tacrolimus with early corticosteroid withdrawal in simultaneous pancreas-kidney transplantation

机译：双抗体诱导和vego使用everolimus在同时胰腺肾移植同时提取皮质类固醇的低剂量标准蛋白酶

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BackgroundTo be an optimal immunosuppressive regimen after simultaneous pancreas kidney transplantation (SPK), low dose calcineurin inhibitor and early withdrawal of corticosteroids are desired. MethodsImmunosuppressive regimen as such has been conducted consecutively in SPK recipients since 2009 in authors' institute. In addition to tacrolimus in low trough level and early corticosteroid withdraw, dual induction with basiliximab and low-dose thymoglobulin in combination with everolimus are the important components of the protocol. Results25 consecutive primary SPK recipients were included in the study. Lymphocyte depletion by low dose thymoglobulin was limited to two weeks, and CD25 coating with basiliximab was detectable for 4?weeks. The BPAR within the first 12?months was 13%. During a median follow-up of 58?months, new-onset diabetes mellitus and renal function deterioration were rare events. No cytomegalovirus activation was encountered. The patients, pancreas and kidney graft survival at 1-year and 5-year was 100% and 94.4%, 95.8% and 95.8%, 100% and 100% respectively.
机译：背景为同时胰腺肾移植（SPK）后的最佳免疫抑制方案，期望低剂量钙素抑制剂和皮质类固醇的早期撤离。方法以自2009年在作者研究所自2009年以来，在SPK受援者中，在SPK接受者中进行了方法。除了在低槽水平和早期皮质类固醇中脱离的Tacrolimus之外，与Basiliximab和低剂量胸腺蛋白的双重诱导与威洛米司组合的是协议的重要组成部分。结果25连续初级SPK接受者纳入该研究。低剂量胸腺蛋白的淋巴细胞耗竭仅限于2周，并且可以检测到Basiliximab的CD25涂层4？周。前12个月内的BPAR是13％。在58个月的中间后续期间，新的糖尿病和肾功能恶化是罕见的事件。没有遇到巨细胞病毒活化。患者，胰腺和肾移植物存活率在1年和5年的100％和94.4％，95.8％和95.8％，100％和100％。

著录项

  • 来源
    《Transplant immunology》 |2018年第2018期|共8页
  • 作者

    Jun Li; Martina Koch; Kathrin Kramer; Katja Kloth; Abdel Rahman Abu Ganim; Silke Scheidat; Franz Rinninger; Friedrich Thaiss; Amit Gulati; Uta Herden; Eike Achilles; Lutz Fischer; Bjoern Nashan;

  • 作者单位

    Department of Hepatobiliary Surgery and Transplantation University Medical Center Hamburg-Eppendorf;

    Department of Hepatobiliary Surgery and Transplantation University Medical Center Hamburg-Eppendorf;

    Department of Hepatobiliary Surgery and Transplantation University Medical Center Hamburg-Eppendorf;

    Department of Hepatobiliary Surgery and Transplantation University Medical Center Hamburg-Eppendorf;

    Department of Hepatobiliary Surgery and Transplantation University Medical Center Hamburg-Eppendorf;

    Department of Internal Medicine University Medical Center Hamburg-Eppendorf;

    Department of Internal Medicine University Medical Center Hamburg-Eppendorf;

    Department of Internal Medicine University Medical Center Hamburg-Eppendorf;

    Department of Medical Biometry and Epidemiology University Medical Center Hamburg-Eppendorf;

    Department of Hepatobiliary Surgery and Transplantation University Medical Center Hamburg-Eppendorf;

    Department of Hepatobiliary Surgery and Transplantation University Medical Center Hamburg-Eppendorf;

    Department of Hepatobiliary Surgery and Transplantation University Medical Center Hamburg-Eppendorf;

    Department of Hepatobiliary Surgery and Transplantation University Medical Center Hamburg-Eppendorf;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 器官移植术;
  • 关键词

    Simultaneous pancreas kidney transplantation; Immunosuppression; Induction; Calcineurin inhibitor; Corticosteroids withdrawal; Complication;

    机译：同时胰腺肾移植;免疫抑制;诱导;钙碱抑制剂;皮质类固醇戒断;并发症;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号